Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia - Wikidata - awgldk - TriplyDB

Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia

Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia

http://www.wikidata.org/entity/Q34008584

about

Management of Chronic Lymphocytic Leukemia in the Elderly Management of elderly and unfit patients with chronic lymphocytic leukemia.Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53 Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Initial treatment of CLL: integrating biology and functional status.Ibrutinib: a paradigm shift in management of CLL.Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.New treatment options for chronic lymphocytic leukemia.A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53.Shifting paradigms in the treatment of chronic lymphocytic leukemia.Promising therapies for the treatment of chronic lymphocytic leukemia.Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.Magic pills: new oral drugs to treat chronic lymphocytic leukemia.Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience.Ibrutinib treatment improves T cell number and function in CLL patients.Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy.Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia.The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia.Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.Immunoglobulin replacement therapy targeting the BCR in chronic lymphocytic leukemia

P2860

Q26775983-A564BA58-B0B2-4CC5-BA0A-098610A774E5 Q30243914-DAAE9DAC-0E5F-4523-ADD6-DFA2DD1AFBC7 Q34137016-924D1A06-8A1C-4D1D-8AC9-43DFD7E2CDEF Q34625543-2182D8F7-695C-4194-8F0C-E1B76D1B846B Q36219647-BC633821-42BD-4565-99AB-62C3594BA0F5 Q36739295-5CB2FCC7-1B59-4EE7-848D-0541A17891FB Q37427107-2D1AE57E-3FF9-407F-A90E-8F52E751B103 Q37694617-5F9686C8-0806-4A71-85B3-06280E023554 Q38190095-3D4612D8-A78A-4D7C-B066-9C32432CEE9D Q38231432-543B18B6-82BD-4C95-ADC8-998D406D6AD3 Q38357127-D162B152-C5AC-4D4D-AC85-CE0F6755D30C Q38366441-682AEFCC-BFEE-45B6-B68B-7B1735971944 Q38594364-27354C27-E1AD-4F98-8D91-805EB5C32368 Q38612199-8616C720-5A6B-4551-A4C9-896E42E250FB Q38646074-6AFE9815-9C3B-400B-A512-7051ED821D45 Q38764077-E957853B-07A2-46A0-B3E3-276326A4E0C3 Q38943877-ABDAF610-5C20-461B-816A-C1B907B7897A Q39034465-14D0332E-86AC-49DF-8025-CD5A3970B58A Q40438184-91891CB4-22D7-432E-B8B4-F7CCEC8EC0BA Q41556347-EB148090-EC40-4F89-BAD9-D2ABAA00D564 Q42909982-5931D6C0-35FB-40FE-B3B7-AFC7C32EADC8 Q43146945-4DDAB5F6-056C-4424-BDE2-0A6AD00CF656 Q47105759-0E32DBBB-71AD-490B-8849-0E7065BC8484 Q49565011-0C1B5F96-CDDC-4335-AE6B-A2748DD8FC14 Q49818481-BDFB5E1B-007F-4D7F-9616-8766D0838A37 Q51007218-FCB18032-6AE9-4D57-BED1-AB4FD0A6CE1D Q58744741-B3D06035-BECD-4DDC-A05A-9A1ACF9D3694

P2860

Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia

http://www.wikidata.org/entity/Q34008584

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

name

Lenalidomide induces long-last ...... h chronic lymphocytic leukemia

@ast

Lenalidomide induces long-last ...... h chronic lymphocytic leukemia

@en

Lenalidomide induces long-last ...... h chronic lymphocytic leukemia

@nl

type

label

Lenalidomide induces long-last ...... h chronic lymphocytic leukemia

@ast

Lenalidomide induces long-last ...... h chronic lymphocytic leukemia

@en

Lenalidomide induces long-last ...... h chronic lymphocytic leukemia

@nl

prefLabel

Lenalidomide induces long-last ...... h chronic lymphocytic leukemia

@ast

Lenalidomide induces long-last ...... h chronic lymphocytic leukemia

@en

Lenalidomide induces long-last ...... h chronic lymphocytic leukemia

@nl

P1433

Q34008584-0A28BEB6-F508-45A4-87AE-43E9951D47D3

P1476

Q34008584-FB46614B-7179-4285-9828-4CF6FCBD8BD8

P2093

Q34008584-0969E42C-66D4-44D0-B05B-A5A2F2E8F37B

Q34008584-367C2C1B-B28E-48B9-AF82-B3F7F62E9358

Q34008584-64553DF8-2738-4F27-932E-6A50F9A09B94

Q34008584-98B920F5-984E-4CBF-BDD9-364CB126C35A

Q34008584-C94CE30E-FCB3-46C2-B38E-C5CA5987799A

Q34008584-DB4D3566-2E98-4C10-98B8-B5E87A42D805

P2860

Q34008584-06729CE9-916F-4BC5-B949-4F3C470B5D7A

Q34008584-31268DD4-CD44-41D5-AB4A-271A29A3D071

Q34008584-3A8FFA28-5C37-42EC-A9C7-91015F5BB28B

Q34008584-43D0AA5F-E4ED-4127-B33B-48FE0EAB3AEE

Q34008584-47B78A23-2E56-44E0-9961-18767820769D

Q34008584-55A62F60-069B-4A33-B45A-4EDA6BEE9542

Q34008584-5D854774-E39E-4F51-8700-8DF43AE57927

Q34008584-6F62DAE8-3E5C-4100-960C-735B96D22C22

Q34008584-7AA0A83F-5B45-44E8-A8EA-802A2E6F08C0

Q34008584-B68E9159-4B0C-43F9-9DF9-8E7F43BAB3C7

P304

Q34008584-9E4A6BDB-C1EE-4C3A-BF79-63A1E4E90766

P31

Q34008584-CAFA6DFD-90CE-41CC-AFAB-EFB28B512D6D

P356

Q34008584-ECAC62BE-6CCF-46F2-A1A9-4732A18F8F6B

P407

Q34008584-AE9AE9AC-28B3-4161-BFC5-A11866763810

P433

Q34008584-848511E0-B794-43B1-9FEF-F91C1D384281

P478

Q34008584-872FE862-492E-46A1-B0CC-989CA8B0DE49

P50

Q34008584-2F37F51E-E030-4F39-9B94-3C85CF8E8D2D

Q34008584-43671A17-2EA6-429E-896F-5B25A9995CEF

Q34008584-61B520F8-C663-45E7-87AF-ADEA199B4A63

Q34008584-64F458E9-1CA7-4BE4-B058-A6F6C7CDE69F

Q34008584-E1CE772E-7B4C-45C6-BADA-AC520CF9DCA7

P577

Q34008584-E2B16DE0-ED0A-4246-8A9B-3F0C201BBCFB

P5875

Q34008584-438128E2-EDA7-4F9C-88F1-1833D3E505BA

P698

Q34008584-82653FDD-3971-4C5D-BD39-137D530FAA2C

P921

Q34008584-6FC2A716-553E-4E44-AED8-956CEFCC9057

Q34008584-9D390007-9AB1-4324-BD64-0ED9FEFC887E

Q34008584-EF32997D-E1FA-448C-B680-9D5845034106

P932

Q34008584-6C87CBFB-AA04-4579-B4D4-799BE18CE7FF

P356

BLOOD-2013-04-495341

P1433

P1476

Lenalidomide induces long-last ...... h chronic lymphocytic leukemia

@en

P2093

Hui Gao

http://www.w3.org/2001/XMLSchema#string

James M Reuben

http://www.w3.org/2001/XMLSchema#string

Paolo Strati

http://www.w3.org/2001/XMLSchema#string

Steliana Calin

http://www.w3.org/2001/XMLSchema#string

Steven M Kornblau

http://www.w3.org/2001/XMLSchema#string

Xavier C Badoux

http://www.w3.org/2001/XMLSchema#string

P2860

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.

Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.

P304

734-737

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-04-495341

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

Alessandra Ferrajoli

William G Wierda

Michael J. Keating

P577

2013-06-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

242017580

http://www.w3.org/2001/XMLSchema#string

P698

23801633

http://www.w3.org/2001/XMLSchema#string

P921

P932

4123325

http://www.w3.org/2001/XMLSchema#string